

98. (New) The process of claim 71 wherein the T cells are from the recipient and the xenoantigen is from the donor.

99. (New) The process of claim 71 wherein said T cells are present in a transplant.

¹⁰⁰
~~101.~~ (New) The process of claim 71 wherein said MSCs are administered to a transplant recipient suffering from graft-versus-host disease.

¹⁰¹
~~102.~~ (New) The process of claim 71 wherein prior to said administration said mesenchymal stem cells (MSCs) have been expanded in culture.

¹⁰²
~~103.~~ (New) The process of claim 71 wherein said effector cells are T cells previously activated and said immune response is the reactivation of said T cells.

¹⁰³
~~104.~~ (New) The process of claim 71 wherein the transplant is skin.

¹⁰⁴
~~105.~~ (New) The process of claim 71 wherein the mesenchymal stem cells are administered to the transplant recipient to treat rejection of the transplant by the recipient.

¹⁰⁵
~~106.~~ (New) The process of claim 71 wherein the mesenchymal stem cells are human mesenchymal stem cells.

¹⁰⁶
~~107.~~ (New) The process of claim 71 further comprising administering to the recipient immunosuppressive agents.

¹⁰⁷
~~108.~~ (New) The process of claim 71 wherein the transplant is a solid organ.

¹⁰⁸
~~109.~~ (New) The process of claim 108 wherein the solid organ is selected from heart, pancreas, kidney, lung or liver.

¹⁰⁹
~~110~~. (New) The process of claim 71 wherein said mesenchymal stem cells are administered prior to said transplant.

¹¹⁰
~~111~~. (New) The process of claim 71 wherein said mesenchymal stem cells are administered concurrently with said transplant.

¹¹¹
~~112~~. (New) The process of claim 71 wherein said mesenchymal stem cells are administered as part of the transplant.

¹¹²
~~113~~. (New) The process of claim 71 wherein the mesenchymal stem cells are administered subsequent to transplant.

¹¹³
~~114~~. (New) The process of claim 71 wherein said mesenchymal stem cells are administered intravenously to the recipient.

¹¹⁴
~~115~~. (New) The process of claim 71 wherein said effector cells are cells of a recipient of said donor transplant.

¹¹⁵
~~116~~. (New) A process for treating a transplant recipient to reduce in said recipient an immune response of effector cells against a xenoantigen to the effector cells, comprising:

transplanting to a transplant recipient a transplant treated with mesenchymal stem cells in an amount effective to reduce an immune response of effector cells against a xenoantigen to the effector cells, whereby in the transplant recipient the effector cells have a reduced immune response against the xenoantigen.

¹¹⁶
~~117~~. (New) The process of claim ¹¹⁵~~116~~ wherein said effector cells are T cells.